查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995169

抗减肥药市场：依治疗方法、药物类型、给药途径、剂型及通路划分－2026-2032年全球市场预测

Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗减肥药市场价值将达到 116.9 亿美元，到 2026 年将成长到 126.7 亿美元，到 2032 年将达到 212.1 亿美元，复合年增长率为 8.87%。

主要市场统计数据
基准年 2025 116.9亿美元
预计年份：2026年 126.7亿美元
预测年份 2032 212.1亿美元
复合年增长率 (%) 8.87%

这是一本权威的指南，旨在为决策者介绍不断发展的抗减肥药生态系统，并提出了科学进步、临床实践和商业性需求的框架。

全球对抗肥胖的努力正加速发展成为一个至关重要的多学科领域，生物医学创新、临床实践、保险公司决策和患者期望在此交汇融合。近年来，我们见证了新药疗法的涌现、外科和内视镜介入技术的进步，以及对长期治疗效果和安全性的日益关注。在此背景下，相关人员必须应对复杂的法规环境、不断变化的报销趋势以及社会对医疗服务可近性和公平性的日益关注。

科学突破、交付方式创新和护理路径重组的清晰融合，正在重塑治疗可能性和商业策略。

科学、监管和商业性因素的共同作用，已将抗减肥药的格局从渐进式改进转变为变革性改变。胜肽类和肠促胰岛素生物学的突破性进展正在重新定义治疗标靶和临床预期，从而刺激了对药物和器械干预措施的新投资。同时，真实世界数据（REWED）和长期临床计画越来越重视安全性讯号和卫生经济学考量，使製造商和支付者能够更早就对患者和医疗保健系统至关重要的结果达成一致。

分析检视近期关税政策如何促进抗肥胖药物整个产品生命週期中的供应链韧性、采购转移和商业性调整。

美国2025年实施的关税措施为抗减肥药供应链中的製造商、经销商和医疗保健提供者带来了新的考量。虽然关税政策只是众多因素之一，但它已对采购、定价策略和分销物流产生了直接的营运影响。受关税影响的原材料采购企业被迫重新审查与供应商的合同，尽可能扩大国内采购，并模拟关税对下游贸易流量和合约义务的影响。

基于策略性细分的洞察，揭示治疗方法、给药方法、配方和分销管道的差异，从而指导开发重点和商业化选择。

细分市场洞察提供了必要的详细观点，以协调临床开发、商业性实施和患者需求。根据治疗类型，市场分为两大类：「药物」和「治疗方法」。在「药物」类别下，我们将更详细地分析安非他酮/纳曲酮、Liraglutide、奥利司他、芬特明/托吡酯、Semaglutide和替泽帕肽。在「治疗方法」类别下，我们将评估可调式胃束带术、内视镜袖状胃成形术和胃绕道手术。这种双轴分析突显了药物创新和手术干预如何在医疗保健路径中并存和竞争，以及慢性药物治疗与一次性或间歇性手术干预在决策上的差异。

对监管、支付方和临床趋势进行详细的区域评估，以确定每个主要全球区域不同的打入市场策略。

区域因素持续影响监管路径、支付方行为、临床实务规范以及病患用药途径，并对产品策略产生重大影响。在美洲，围绕保险覆盖范围和可负担性的政策辩论与临床医生对新药日益深入的了解交织在一起，这既为药物的可及性创造了机会，也带来了提供可靠疗效数据的压力。在该地区运营的製药企业必须平衡积极的证据产生、积极的支付方参与以及患者支持能力，以确保药物的可持续推广。

一份全面的竞争分析报告，揭示了製药、生物技术和医疗设备公司如何透过证据、伙伴关係和综合护理解决方案实现差异化。

抗减肥药的竞争格局呈现出多元化的格局，大型製药企业，也有高度专业化的生物技术公司，还有专注于医疗设备的公司，它们都致力于将临床差异化与可扩展的商业化相结合。成熟的生物製药公司利用其研发专长和全球分销网络，拓展适应症范围并进行全生命週期管理；而生物技术公司则往往专注于新颖的作用机制、目标患者群体以及以伙伴关係主导的商业化。

为高阶主管提供可操作的、高优先级的行动方案，以协调证据生成、患者支持、供应弹性和伙伴关係，从而实现可持续的商业性成功。

为了将科学预期转化为永续的影响，产业领导者应优先采取以下几个切实可行的步骤。首先，透过将卫生经济学终点和可操作的结果纳入主要试验和上市后监测，使临床开发与支付方的证据需求保持一致。这将缩短获得保险覆盖所需的时间，并降低获得治疗的门槛。其次，要认识到真实世界中的治疗依从性是长期治疗价值的关键驱动因素，并投资于以患者为中心的支持模式，以解决治疗启动、药物依从性和耐受性管理等问题。

为了支持结论，我们采用了一种透明的混合方法研究途径，结合了相关人员访谈、临床文献综述、监管分析和基于情境的整合。

本研究采用混合方法，整合一手与二手研究，以提供严谨且多角度的观点。一手研究包括对临床机构、保险公司、製药业和分销管道等相关人员进行结构化访谈，并辅以对监管指南和公开临床试验註册资讯的详细审查。二手分析包括同行评审的临床文献、最新的安全性资讯和已发布的卫生技术评估决定，确保依证反映疗效和真实世界表现。

简明扼要地整合策略挑战，强调证据、病人就医途径和综合照护模式是产生长期影响的决定性因素。

总之，抗减肥药市场已进入成熟阶段，其特点是科学取得了显着进步，人们对药物安全性和长期疗效的期望不断提高，以及复杂的商业性动态，包括供应链和政策方面的考虑。在此环境下取得成功取决于能否提供令人信服的对比证据，开发以患者为中心的支援项目，并调整商业模式以降低定价和采购风险。同时，能够整合药物创新、手术方案和数位化支持，从而提供全面且永续的治疗路径的公司，也拥有许多发展机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：治疗方法分類的抗减肥药市场

  • 製药
    • 安非他酮纳曲酮
    • Liraglutide
    • 奥利司他
    • 托吡拉芬特明
    • Semaglutide
    • Tirzepatide
  • 治疗方法
    • 可调式胃束带手术
    • 内视镜袖状胃切除术
    • 胃绕道手术

第九章：按药物类型分類的抗减肥药市场

  • 非处方药
  • 处方药

第十章：抗减肥药市场：依给药途径划分

  • 口服
    • 胶囊
    • 药片
  • 肠外给药
    • 静脉
    • 皮下

第十一章 以剂型分類的减肥药市场

  • 液体
  • 半固态製剂
  • 固态剂型

第十二章：抗减肥药市场：依通路划分

  • 医院、诊所、药房
  • 网路药房
  • 零售药房

第十三章：抗减肥药市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：抗减肥药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：抗减肥药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国抗减肥药市场

第十七章：中国抗减肥药市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alizyme PLC
  • Amgen Inc.
  • Arena Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • FlaxoSithKline plc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Nalpropion Pharmaceuticals Inc.
  • Norgine BV
  • Novartis AG
  • Novo Nordisk A/S
  • Orexigen Therapeutics Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi SA
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market was valued at USD 11.69 billion in 2025 and is projected to grow to USD 12.67 billion in 2026, with a CAGR of 8.87%, reaching USD 21.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.69 billion
Estimated Year [2026] USD 12.67 billion
Forecast Year [2032] USD 21.21 billion
CAGR (%) 8.87%

An authoritative orientation to the evolving anti-obesity therapeutics ecosystem that frames scientific advances, clinical practice, and commercial imperatives for decision-makers

The global effort to confront obesity has accelerated into a high-stakes, multidisciplinary arena where biomedical innovation, clinical practice, payer decisions, and patient expectations converge. Recent years have seen the emergence of novel pharmacotherapies, evolving surgical and endoscopic interventions, and an intensified focus on long-term outcomes and safety. Against this backdrop, stakeholders must navigate a complex regulatory environment, shifting reimbursement signals, and growing public attention to access and equity.

This executive summary synthesizes the most consequential developments shaping the anti-obesity therapeutics landscape today. It is written for executives, clinical leaders, policy advisors, and investors who require a concise, evidence-based orientation to the opportunities and operational challenges ahead. In the sections that follow, we summarize transformative scientific shifts, assess the implications of new tariff policies introduced in the United States in 2025, unpack granular segmentation insights, distill regional dynamics, profile competitive positioning, and propose concrete actions to accelerate patient access while protecting commercial value. Taken together, these insights aim to enable informed decisions that balance innovation, safety, and sustainable market execution.

A clear synthesis of the scientific breakthroughs, delivery innovations, and care pathway realignments that are reshaping therapeutic possibilities and commercial strategies

The landscape for anti-obesity therapeutics has shifted from incremental improvement to transformational change as a result of converging scientific, regulatory, and commercial forces. Breakthroughs in peptide and incretin biology have redefined therapeutic targets and clinical expectations, prompting renewed investment in both pharmacologic and device-based interventions. At the same time, real-world evidence and longer-duration clinical programs have elevated safety signaling and health-economic considerations, causing manufacturers and payers to align earlier on outcomes that matter to patients and systems.

Concurrently, delivery innovations and route-of-administration strategies have altered patient adherence paradigms and opened new channels for engagement. This has driven the emergence of integrated care pathways that combine medication, device, digital support, and behavioral interventions for sustained weight management. As a result, clinical development programs increasingly prioritize durability of effect, tolerability, and comparative effectiveness, while commercialization strategies emphasize differentiated value propositions, patient support services, and partnerships with specialty and primary care providers. These transformative shifts require stakeholders to adopt agile evidence-generation plans and holistic go-to-market models that span product, payer, and provider ecosystems.

An analytical account of how recent tariff policies have compelled supply chain resilience, sourcing shifts, and commercial coordination across anti-obesity product lifecycles

The tariff measures enacted in the United States in 2025 introduced new considerations for manufacturers, distributors, and providers involved in the supply chain for anti-obesity therapeutics. Although tariff policy is only one factor among many, it has immediate operational implications for sourcing, pricing strategies, and distribution logistics. Organizations exposed to tariff-affected inputs have had to reassess supplier contracts, ramp up domestic sourcing where feasible, and model the downstream effects on trade flows and contractual obligations.

Beyond procurement, the tariffs have prompted more active cross-functional coordination within companies, compelling commercial, regulatory, and supply teams to collaborate on mitigation strategies that preserve patient access while protecting margins. For some manufacturers, the policy environment accelerated plans to localize certain production activities or to reconfigure product packaging and distribution hubs to minimize tariff exposure. For payers and providers, the tariffs have emphasized the importance of transparent pricing conversations and proactive engagement on formulary placement and prior authorization processes. In short, the cumulative impact of the 2025 tariffs has been to highlight supply chain resilience and strategic sourcing as central components of commercial planning for anti-obesity therapeutics.

Strategic segmentation-driven insights that reveal therapeutic, delivery, formulation, and channel distinctions guiding development priorities and commercialization choices

Segmentation insights provide the granular perspective necessary to align clinical development with commercial execution and patient needs. Based on Treatment Type, the market is studied across Medications and Treatments, with Medications further examined across Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide, while Treatments are evaluated across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery. This dual axis highlights how pharmaceutical innovation and procedural interventions coexist and compete within care pathways, and how decision-making differs between chronic pharmacotherapy and one-time or episodic procedural interventions.

Based on Drug Type, the market is studied across Over-The-Counter Drugs and Prescription Drugs, reflecting distinct regulatory regimes, patient self-care behaviors, and payer interactions that influence access and adherence. Based on Route Of Administration, the market is studied across Oral Administration and Parenteral Administration, with Oral Administration further examined across Capsules and Tablets, and Parenteral Administration further examined across Intravenous and Subcutaneous, underscoring how delivery mode drives clinical adoption, patient preference, and health-system readiness. Finally, based on Drug Formulation, the market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms, while distribution considerations are captured based on Distribution Channel where the market is studied across Hospitals & Clinics Pharmacies, Online Pharmacies, and Retail Pharmacies. Together, these segmentation lenses reveal where innovation clusters, where reimbursement friction is most likely to occur, and where targeted evidence generation and patient support investments can produce the greatest commercial leverage.

A nuanced regional assessment of regulatory, payer, and clinical dynamics that dictates differentiated go-to-market tactics across major global territories

Geography continues to shape regulatory pathways, payer behavior, clinical practice norms, and patient access in ways that materially influence product strategy. In the Americas, policy debates around coverage and affordability intersect with growing clinician familiarity with novel agents, creating both access opportunities and pressure for robust outcomes data. Manufacturers operating in this region must balance aggressive evidence-generation with proactive payer engagement and patient support capabilities to ensure sustained uptake.

In Europe, Middle East & Africa, heterogeneity across national systems requires differentiated market entry and pricing strategies, with some jurisdictions prioritizing cost-effectiveness evidence and others focusing on therapeutic value in specific patient cohorts. This region often demands more localized health-economic models and targeted post-launch real-world studies. In Asia-Pacific, rapid adoption of new therapies in select urban centers is counterbalanced by variable reimbursement frameworks and supply chain complexity; the region therefore rewards flexible distribution models and partnerships with established regional healthcare providers. Across all regions, cross-border collaboration on regulatory science and harmonized approaches to safety monitoring can accelerate appropriate access while protecting patient welfare.

A comprehensive competitive synthesis revealing how pharmaceutical, biotechnology, and device firms differentiate through evidence, partnerships, and integrated care solutions

Competitive dynamics in anti-obesity therapeutics reflect a mix of large diversified pharmaceutical firms, specialized biotechs, and device-focused companies, each pursuing strategies that combine clinical differentiation with scalable commercialization. Established biopharmaceutical companies leverage development expertise and global distribution networks to pursue broad indications and lifecycle management, while biotechs frequently focus on novel mechanisms of action, targeted patient segments, and partnership-driven commercialization.

Device and procedural players emphasize outcomes that matter in surgical and endoscopic interventions, investing in training, center-of-excellence models, and integration with ambulatory care pathways. Across all company types, strategic priorities include demonstrating comparative effectiveness versus existing standards, developing patient support ecosystems that improve adherence and persistence, and building payer evidence that links clinical outcomes to economic benefit. As competition intensifies, alliances between drug and device innovators, digital health providers, and specialty care networks are likely to increase, reflecting a marketplace where integrated solutions that span prevention, treatment, and long-term management create durable competitive advantages.

Practical and prioritized actions for executives to align evidence generation, patient support, supply resilience, and partnerships for durable commercial success

To convert scientific promise into sustainable impact, industry leaders should prioritize several actionable moves. First, align clinical development with payer evidence needs by embedding health-economic endpoints and pragmatic outcomes into pivotal and post-marketing studies; this will shorten time-to-coverage discussions and reduce access friction. Second, invest in patient-centric support models that address initiation, adherence, and tolerability management, recognizing that real-world persistence is a critical driver of long-term therapeutic value.

Third, strengthen supply chain resilience through diversified sourcing and regional manufacturing where appropriate, thereby mitigating tariff exposure and ensuring consistent product availability. Fourth, pursue partnerships that integrate pharmacologic treatments with device-based interventions, digital therapeutics, and behavioral programs to create differentiated value propositions for clinicians and payers. Finally, engage proactively with regulators and payers to design adaptive evidence-generation pathways that can incorporate real-world data and conditional coverage arrangements. By operationalizing these recommendations, organizations can accelerate responsible access while safeguarding commercial viability.

A transparent mixed-methods research approach combining stakeholder interviews, clinical literature review, regulatory analysis, and scenario-based synthesis to underpin conclusions

This research draws on a mixed-methods approach that integrates primary and secondary sources to deliver a rigorous, multi-dimensional perspective. Primary research includes structured interviews with stakeholders across clinical, payer, industry, and distribution channels, supplemented by detailed reviews of regulatory guidance and publicly available clinical trial registries. Secondary analysis encompassed peer-reviewed clinical literature, safety updates, and published health-technology assessment decisions to ensure the evidence base reflects both efficacy and real-world performance.

Analytical methods combined thematic synthesis with scenario analysis to explore strategic sensitivities such as reimbursement shifts, supply chain interruptions, and evolving standard-of-care practices. Where appropriate, triangulation across data sources was used to validate findings and highlight areas of consensus or divergence among stakeholders. The methodology emphasizes transparency in source attribution and methodological choices so that readers can assess the applicability of insights to their specific operating contexts.

A concise synthesis of strategic imperatives emphasizing evidence, patient access, and integrated care models as decisive factors for long-term impact

In conclusion, the anti-obesity therapeutics landscape is entering a maturation phase defined by meaningful scientific progress, heightened expectations for safety and long-term outcomes, and complex commercial dynamics that include supply chain and policy considerations. Success in this environment will depend on the ability of organizations to generate compelling comparative evidence, deploy patient-centric support programs, and adapt operational models to mitigate tariff and sourcing risks. At the same time, opportunities abound for those who can integrate pharmacologic innovation with procedural options and digital supports to deliver comprehensive, sustainable care pathways.

Going forward, stakeholders who combine rigorous clinical development, agile commercial execution, and proactive payer engagement will be best positioned to translate breakthroughs into widespread, equitable patient access. The strategic choices made now-about evidence strategy, partnerships, and organizational capabilities-will determine which therapies achieve lasting clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Therapeutics Market, by Treatment Type

  • 8.1. Medications
    • 8.1.1. Bupropion-Naltrexone
    • 8.1.2. Liraglutide
    • 8.1.3. Orlistat
    • 8.1.4. Phentermine-Topiramate
    • 8.1.5. Semaglutide
    • 8.1.6. Tilzepatide
  • 8.2. Treatments
    • 8.2.1. Adjustable Gastric Banding
    • 8.2.2. Endoscopic Sleeve Gastroplasty
    • 8.2.3. Gastric Bypass Surgery

9. Anti-Obesity Therapeutics Market, by Drug Type

  • 9.1. Over-The-Counter Drugs
  • 9.2. Prescription Drugs

10. Anti-Obesity Therapeutics Market, by Route Of Administration

  • 10.1. Oral Administration
    • 10.1.1. Capsules
    • 10.1.2. Tablets
  • 10.2. Parenteral Administration
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous

11. Anti-Obesity Therapeutics Market, by Drug Formulation

  • 11.1. Liquid Dosage Forms
  • 11.2. Semi-Solid Dosage Forms
  • 11.3. Solid Dosage Forms

12. Anti-Obesity Therapeutics Market, by Distribution Channel

  • 12.1. Hospitals & Clinics Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Anti-Obesity Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-Obesity Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-Obesity Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anti-Obesity Therapeutics Market

17. China Anti-Obesity Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alizyme PLC
  • 18.6. Amgen Inc.
  • 18.7. Arena Pharmaceuticals Inc.
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Currax Pharmaceuticals LLC
  • 18.11. Eisai Co. Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. F. Hoffmann-La Roche Ltd
  • 18.14. FlaxoSithKline plc.
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Johnson & Johnson Services Inc.
  • 18.17. Merck & Co. Inc.
  • 18.18. Nalpropion Pharmaceuticals Inc.
  • 18.19. Norgine B.V.
  • 18.20. Novartis AG
  • 18.21. Novo Nordisk A/S
  • 18.22. Orexigen Therapeutics Inc.
  • 18.23. Pfizer Inc.
  • 18.24. Rhythm Pharmaceuticals, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. SHIONOGI & Co., Ltd.
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Vivus Inc.
  • 18.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)